article thumbnail

: Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rally

MarketWatch

IOVA on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administration for lifileucel — a therapy intended to combat advanced melanoma in some cases. Biotech cancer-treatment developer Iovance Biotherapeutics Inc.

License 40
article thumbnail

Saturday links: too much mobile

Abnormal Returns

theatlantic.com) Food Food waste is an underappreciated cause of climate change. fastcompany.com) Why food halls are popping up seemingly everywhere. nytimes.com) Are alternative licensing programs the solution to teacher shortages? (wsj.com) Dogs What the rising use of canine anti-anxiety medications tells us.

Food 220
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Saturday links: too much mobile

Abnormal Returns

theatlantic.com) Food Food waste is an underappreciated cause of climate change. fastcompany.com) Why food halls are popping up seemingly everywhere. nytimes.com) Are alternative licensing programs the solution to teacher shortages? (wsj.com) Dogs What the rising use of canine anti-anxiety medications tells us.

Food 130
article thumbnail

Saturday links: impromptu fun

Abnormal Returns

bloomberg.com) Why people continue to drive on suspended licenses. nber.org) Food How water shortages are going to affect food prices. Autos What it means if California bans the sale of new ICE vehicles by 2035. newatlas.com) Bigger tires make for lower mileage and range. curbed.com) Transport Pilot Co.,

Food 130
article thumbnail

: Sarepta stock surges more than 10% as results top expectations, drug given priority review

MarketWatch

The company also said the biologics license application for SRP-9001 was granted priority review by the Food and Drug Administration, with an expected decision by May 29. Revenue rose to $258.4 million from $201.5 million in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of $1.47 a share on revenue of $250.4

License 75
article thumbnail

: ImmunityBio stock loses more than half its value after disclosing FDA can’t approve the BLA for its cancer treatment in its present form

MarketWatch

Food and Drug Administration, but puts the company’s Biologics License Application (BLA) for its bladder cancer treatment Anktiva (N-803) on hold. The FDA determined that it can’t approve the BLA in its present form as a pre-license inspection of the company’s third-party contract manufacturer found deficiencies.

License 40
article thumbnail

Hurricane and Natural Disaster Preparedness

Your Richest Life

The number varies, but $1,000-$2,000 in cash is about the ballpark for covering travel costs, gas, food, etc. And remember, you likely won’t have time to gather these before a storm, so try to keep them together somewhere safe and easy to find: Driver’s licenses and Social Security cards. Food Storage. Birth certificates.

Food 104